Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $112.65 (market cap $16.78B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares 3 7 Year Treasury Bond ETF is far larger — about 3.4× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 45 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| IEI | TVTX | |
|---|---|---|
Market Cap | $16.78B | $4.88B |
Volume | 2,469,699 | 1,668,577 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $67.52 |
52-Week Low | $113.17 | $26.79 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI is trading at $113.57 with minimal daily movement (+0.08%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The stock faces resistance at $114 and support at $113. Recent dividend payments of $0.37-$0.38 per share demonstrate shareholder returns, but key valuation metrics (P/E, P/S, P/B) are unavailable for fundamental assessment.
The outlook remains cautious due to the bearish technical setup and lack of fundamental visibility. Bond market volatility highlighted in recent news (Bloomberg, Reuters September 2026) could impact financial sector sentiment. Investment appeal hinges on forthcoming financial disclosures to validate valuation, while current technical resistance near $114 limits near-term upside potential.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
